Eli Lilly Drug Shows New Potential in Curbing Food CravingsEli Lilly’s GLP-1 weight-loss drug tirzepatide — sold as Mounjaro and Zepbound — may do more than suppress appetite. A new Nature Medicine report shows that in one patient with severe binge-eating behavior, the drug appeared to silence food-craving signals in the brain’s reward center. This is the first direct recording of brain activity in a person receiving tirzepatide, offering rare insight into how GLP-1 drugs may reduce “food noise.”
Researchers from the University of Pennsylvania monitored the brain activity of four patients undergoing deep-brain stimulation for loss-of-control eating disorders. Only one was already taking tirzepatide. During electrode monitoring, her nucleus accumbens — the core craving region — showed no binge-triggering activity, and she experienced no food preoccupation. The other three patients showed the usual spikes in brain activity before cravings. While the findings cannot be generalized due to the small sample size, researchers believe this opens a door for exploring GLP-1 drugs as potential treatments for certain eating disorders.
Technically, Eli Lilly’s stock continues its strong bullish structure. Price recently broke above a major resistance zone at $960, pushing into new all-time highs. With this breakout, the market may wait for a clean retest of former resistance — now support — before another upward continuation. The next psychological levels to watch remain $1,100 and $1,200, which could act as future resistance zones if momentum continues.
